{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:43:50Z","timestamp":1786866230704,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.canlet.2021.12.031","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T21:42:39Z","timestamp":1640900559000},"page":"37-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer"],"prefix":"10.1016","volume":"529","author":[{"given":"Lei","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suding","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-5775","authenticated-orcid":false,"given":"Bing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.12.031_bib1","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.12.031_bib2","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.12.031_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2021.12.031_bib4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","article-title":"Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening","volume":"21","author":"Boretto","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2021.12.031_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2018.05.015","article-title":"Endometrial cancer: molecular markers and management of advanced stage disease","volume":"150","author":"Arend","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","article-title":"Harnessing cancer immunotherapy during the unexploited immediate perioperative period","volume":"17","author":"Matzner","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.12.031_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic characterization of endometrial carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.12.031_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib10","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI133055","article-title":"A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy","volume":"130","author":"Theivanthiran","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.12.031_bib11","doi-asserted-by":"crossref","first-page":"107454","DOI":"10.1016\/j.pharmthera.2019.107454","article-title":"Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer","volume":"207","author":"Malone","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2021.12.031_bib12","first-page":"8647","article-title":"Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway","volume":"61","author":"Seliger","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.031_bib13","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.031_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1151593","article-title":"NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes","volume":"5","author":"Rodriguez","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.12.031_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12165","article-title":"Autophagy in the immune system","volume":"141","author":"Puleston","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2021.12.031_bib16","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41467-020-17395-y","article-title":"Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.12.031_bib17","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.celrep.2016.04.002","article-title":"Macroautophagy proteins control MHC class I levels on dendritic cells and shape anti-viral CD8(+) T cell responses","volume":"15","author":"Loi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.12.031_bib18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/2159-8290.CD-RW2020-063","article-title":"Autophagy inhibition synergizes with immunotherapy in pancreatic cancer","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.12.031_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.fertnstert.2018.06.028","article-title":"NLRC5 and autophagy combined as possible predictors in patients with endometriosis","volume":"110","author":"Zhan","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.canlet.2021.12.031_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neo.2017.11.003","article-title":"Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving IL-27-stimulated cytotoxicity of NK cells","volume":"20","author":"Zhou","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2021.12.031_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2015.03.053","article-title":"The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition","volume":"137","author":"Fukuda","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib22","first-page":"2127","article-title":"Immunohistochemical demonstration of peptide hormones in endometrial carcinomas","volume":"54","author":"Inoue","year":"1984","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.canlet.2021.12.031_bib23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2021.12.031_bib24","first-page":"802","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.canlet.2021.12.031_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2021.12.031_bib26","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1200\/JCO.2009.22.3883","article-title":"Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and\/or recurrent solid tumors","volume":"27","author":"Kaumaya","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib27","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1158\/1078-0432.CCR-08-0991","article-title":"Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model","volume":"14","author":"Yoshida","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.031_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2021.12.031_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176181","article-title":"Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion","volume":"12","author":"Albacker","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2021.12.031_bib30","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.27449","article-title":"Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas","volume":"131","author":"de Jong","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2021.12.031_bib31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ijc.30489","article-title":"The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration","volume":"140","author":"Perea","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2021.12.031_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nri3339","article-title":"NLRC5: a key regulator of MHC class I-dependent immune responses","volume":"12","author":"Kobayashi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.12.031_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12026-019-09111-w","article-title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-gamma in MHC-I-deficient breast cancer cells","volume":"67","author":"Zhao","year":"2019","journal-title":"Immunol. Res."},{"key":"10.1016\/j.canlet.2021.12.031_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.12.031_bib35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41418-019-0297-6","article-title":"Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation","volume":"26","author":"Germic","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2021.12.031_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/cdd.2013.48","article-title":"Danger signalling during cancer cell death: origins, plasticity and regulation","volume":"21","author":"Garg","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2021.12.031_bib37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.12.031_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fcimb.2018.00403","article-title":"NLRX1 negatively regulates group A Streptococcus invasion and autophagy induction by interacting with the Beclin 1-UVRAG complex","volume":"8","author":"Aikawa","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.canlet.2021.12.031_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ni.1823","article-title":"Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry","volume":"11","author":"Travassos","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2021.12.031_bib40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/15548627.2020.1752548","article-title":"Autophagy in the physiological endometrium and cancer","volume":"17","author":"Devis-Jauregui","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2021.12.031_bib41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15548627.2016.1271512","article-title":"Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer","volume":"13","author":"Eritja","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2021.12.031_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/imr.12422","article-title":"Autophagy proteins in antigen processing for presentation on MHC molecules","volume":"272","author":"Munz","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2021.12.031_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.12.031_bib44","doi-asserted-by":"crossref","first-page":"E6371","DOI":"10.1073\/pnas.1706504114","article-title":"Autophagy-related protein Vps34 controls the homeostasis and function of antigen cross-presenting CD8alpha(+) dendritic cells","volume":"114","author":"Parekh","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.031_bib45","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/15548627.2015.1045178","article-title":"Differential use of autophagy by primary dendritic cells specialized in cross-presentation","volume":"11","author":"Mintern","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2021.12.031_bib46","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41598-021-82729-9","article-title":"NLRC5\/CITA expression correlates with efficient response to checkpoint blockade immunotherapy","volume":"11","author":"Yoshihama","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:01:23Z","timestamp":1759593683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521006480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"alternative-id":["S0304383521006480"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.031","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1018081\/v1","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}